CA002 peanut allergy immunotherapy readiness for Phase 3 clinical trials in children

Peanut allergy is the most common cause of severe reactions and food allergy deaths in children and adults. The continuous need to manage these risks profoundly reduces quality of life of allergy sufferers and their families.

Camallergy is pioneering a novel biological oral immunotherapy drug CA002 for the treatment of peanut allergy to protect patients from severe reactions should they accidentally eat food containing peanut. It aims to provide protection within 12 weeks of starting treatment significantly improving quality of life. The treatment regime desensitises patients by gradual exposure to increasing amounts of characterised allergenic proteins and involves seven short treatment visits and two years of easy, daily administration. The early access programme at Cambridge Peanut Allergy Clinic has achieved \>95% success in over 200 children. This project will bring CA002 treatment closer to large-scale and international commercialisation. It includes all pre-trial work required to gain approval to initiate global clinical trials that aim to confirm the success of CA002 at Cambridge Peanut Allergy Clinic.

Camallergy's primary customers are allergy physicians (around 4,500 in US, 12,000 in Europe). Peanut allergy represents a potential £multi-billion market with a critical unmet need. Approximately 6m people in the EU and US have a peanut allergy, including 3m children. Based on feedback from international key opinion leaders and our experience at the Cambridge Peanut Allergy Clinic, we anticipate strong demand for safe, efficacious, patient-centric treatments.